Therefore, before ADAR1-targeted therapeutic strategies can be advanced, long-term (e.g., lifespan) studies may be required to investigate the direct effects of ADAR1 in vivo on age- and AD-related neuroinflammation, as well as other health outcomes. Here, ADAR is linked to Alzheimer disease.